Effects of ranibizumab on exudative disciform scars.

BACKGROUND AND

OBJECTIVE

To evaluate the effect of intravitreal ranibizumab in patients with leaking disciform scars.

PATIENTS AND

METHODS

In this retrospective case series, 31 eyes received one or two ranibizumab injections for treatment of choroidal neovascularization. Visual acuity, central retinal thickness, and macular volume were measured prior to injection and at 1-month follow-up.

RESULTS

After one injection (n = 31), mean optical coherence tomography (OCT) central foveal thickness decreased from 317 to 242 microm (P = .00016). Mean OCT macular volume decreased from 7.89 to 6.80 mm3 (P = .00019). After two injections (n = 12), mean OCT central foveal thickness decreased from 310 to 248 microm following the second injection (P = .04). Mean OCT macular volume decreased from 7.80 to 6.43 mm3 at 1-month follow-up after a second injection (P = .006). There was no significant change in visual acuity after injections.

CONCLUSION

In the short-term, ranibizumab decreases the leakage associated with choroidal neovascularization in chronic macular degeneration.